Acerus announced that its agreement with an affiliate of Endo International plc regarding the commercialization of Natesto (testosterone) nasal gel in the United States and Mexico will be terminated as of June 30, 2016. Endo will continue to sell and distribute Natesto in the United States until the date of termination.
Natesto nasal gel, a CIII controlled substance, was initially approved in May 2014 and launched in March 2015. Acerus stated its plans to find a new Natesto partner in the United States to continue the supply.
Natesto nasal gel is an androgen indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. These conditions include congenital or acquired primary hypogonadism and congenital or acquired hypogonadotropic hypogonadism.
Natesto nasal gel is available as a metered dose pump containing 60 actuations. Each pump delivers 5.5 mg of testosterone in 0.122 g gel.
- Acerus Announces Termination of NATESTO™ Agreement with Endo [news release]. Toronto, Canada: Acerus Pharma; December 31, 2015. http://www.aceruspharma.com/English/news/press-release-details/2015/Acerus-Announces-Termination-of-NATESTO-Agreement-with-Endo/default.aspx. Accessed December 31, 2015.
This article originally appeared on MPR